Skip to content

Open for responses

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

DEPT OF DEFENSE

Notice type
Solicitation
Solicitation #
HT9402-27-Q-9102
NAICS
325412
PSC
6505
Posted
November 12, 2026
Response due
November 30, 2026
Place of performance
San Antonio, TX

What this opportunity is

The Department of Defense is seeking quotes for pharmaceutical agents to support the Military Health System's Uniform Formulary through Blanket Purchase Agreements and Additional Discount Program Agreements. This solicitation, under NAICS code 325412, is suitable for small businesses in the pharmaceutical sector. Interested vendors should note the pre-quotation teleconference on November 17, 2026, and prepare to submit responses to clinical questions via email by the specified deadline in the RFQ document.

Analysis by Mindy, grounded in the SAM.gov notice.

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Source: SAM.gov, as posted. Verify the current solicitation before responding.

Pursue this opportunity with Mindy

See who holds it now, who else is bidding, and draft your response — grounded in real government data, not generic AI.

View the original notice on SAM.gov ↗

Open opportunities in NAICS 325412